FP008 is designed for patients with solid tumors that have not responded to existing immunotherapies targeting PD-1.

Results from a Phase III study in pediatric patients demonstrated that Odactra reduced the total combined rhinitis score by 22% compared to placebo.

Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing ...

In this Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, addresses how tariffs will affect pharmaceutical costs and which drug categories will be most affected.

Results from a Phase III registrational study suggest that ecopipam has potential as a first-in-class dopamine-1 receptor ...

The Alpha Cognition executive discusses recent developments that positively impact the upcoming launch for ZUNVEYL.

Zimmer Biomet Holdings launched a new educational campaign targeting people living with joint pain. 1 The campaign is ...

FDA recently announced new safety requirements for DPD screening in cancer patients. Kristine Ashcraft, founder and CEO of ...

In this Pharmaceutical Executive video interview, Jen Butler, Chief Commercial Officer for Pleio, shares some best practices on finding trustworthy and verified information about a new prescription or ...

The BrainSense adaptive deep brain stimulation system personalizes therapy by dynamically adjusting stimulation based on real-time brain activity to improve Parkinson disease symptom control without ...

Will the Industry Rise to the Occasion?

The Phase III SERENA-6 trial is the first global trial to use a circulating tumor DNA-guided approach to detect endocrine ...